NTRK
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
FDA Approves Bristol Myers Squibb's Augtyro in NTRK-Positive Refractory Solid Tumors
The agency granted the drug accelerated approval in patients with previously treated, advanced or metastatic solid tumors harboring NTRK gene fusions.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
Premium
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
BMS Seeking US Approval for Augtyro in Adult, Pediatric Patients With NTRK-Positive Tumors
The firm is seeking a tumor-agnostic indication for the drug based on results from the Phase I/II TRIDENT-1 and CARE trials.
Feb 16, 2022
Jan 27, 2021